Unicycive Therapeutics, Inc.
UNCYDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How UNCY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Oxylanthanum Carbonate | Phase 2 | Chronic Kidney Disease Requiring Chronic Dialysis | - | Patent 2030 |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Unicycive Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Unicycive Therapeutics, Inc.'s (UNCY) pipeline across Phase 2. Its lead program is Oxylanthanum Carbonate (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Unicycive Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Unicycive Therapeutics, Inc. (UNCY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track UNCY biotech catalysts?→
Add UNCY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Unicycive Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.